ArticleJournal of traditional Chinese medicine = Chung i tsa chih ying wen pan2026
Candidate biomarker identification for blood stasis syndrome among coronary artery disease patients using the Olink proteomics platform.
Article in Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
objectiveTo identify candidate biomarkers of blood stasis syndrome (BSS) associated with coronary artery disease (CAD) and explore the underlying inflammatory mechanisms.
methodsUsing the Olink Target 96 Inflammation panel, we identified plasma proteins in a group of 88 patients comprised of healthy controls (HCs), those with CAD and BSS (CAD-BSS), those with CAD without BSS (CAD-non-BSS), and those with BSS without CAD (non-CAD-BSS) (
resultsPatients with CAD had 31/92 upregulated and 4/92 downregulated proteins compared with those without. Chemokine (C-C motif) ligand 11 (CCL11), CUB domain-containing protein 1, hepatocyte growth factor, sirtuin 2 (SIRT2), eukaryotic translation initiation factor 4E-binding protein 1 (4E-BP1), CCL25, and tumor necrosis factor (TNF) showed the strongest upregulation (all
conclusionsResults suggest that the inflammatory response and mechanistic target of rapamycin signaling pathway participate in CAD and BSS development, and that SIRT2 and 4E-BP1 are prospective protein biomarkers for patients with CAD and BSS.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.